Last reviewed · How we verify
LY3090106
At a glance
| Generic name | LY3090106 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome (PHASE2, PHASE3)
- A Study of LY3090106 in Japanese and Caucasian Healthy Participants (PHASE1)
- A Study of LY3090106 in Participants With Sjögren's Syndrome (SS) (PHASE1)
- A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3090106 CI brief — competitive landscape report
- LY3090106 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI